Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
NCT05739383Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2023
- Primary completion
- Apr 2029
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 42
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic cardiovascular disease (ASCVD) comparing Inclisiran sodium 300mg with Placebo (2 arms). Primary endpoint: Time to the first occurrence of 4-Point Major Adverse Cardiovascular Events at 75 months. Started Mar 2023; status: active, not recruiting.
02
Drugs
inclisiran
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT05739383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05739383.